What is the 13F Pro Quality Score for DCGO?

13F Pro ranks DocGo Inc. (DCGO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DCGO's current score at https://13fpro.ai/company/DCGO (free sign-up required for the full ranking).

Which hedge funds own the most DCGO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of DCGO include VANGUARD CAPITAL MANAGEMENT, P.A.W. CAPITAL, Knott David M Jr. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/DCGO as soon as new 13F filings post.

Where does 13F Pro source DCGO data?

All DocGo Inc. fundamentals and ownership data come directly from SEC EDGAR. DocGo Inc. files with the SEC under CIK 1822359. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DCGO in?

DocGo Inc. (DCGO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is DCGO research updated on 13F Pro?

DCGO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

DocGo Inc.(DCGO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1822359 DCGO stock profile & AI dashboard →

13F Pro Quality Score

15.2/100

Rank #2,857 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

1.4/100

Profitability

8.9/100

Balance Sheet

2.4/100

Earnings Quality

45.4/100

Free Cash Flow

17.4/100

Institutional Flow

9.8/100

Revenue Scale

29.1/100

Dilution Risk

23.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why DCGO Scores 15/100

exact factor attribution · 2026-09-11

DCGO's composite is held back by revenue growth and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings quality

-0.5 pts

45th pct

Shareholder dilution

-1.3 pts

24th pct

Institutional flow

-2.0 pts

10th pct

Earnings growth

-2.3 pts

4th pct

Scale

-3.1 pts

29th pct

Capital efficiency

-4.8 pts

2th pct

Free cash flow

-4.9 pts

17th pct

Profitability

-6.2 pts

9th pct

Revenue growth

-9.7 pts

1th pct

Latest change (2026-08-19): 21 → 18 · ↓ Free cash flow 46→19; ↓ earnings_quality 48→40

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

DCGO Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for DocGo Inc. (DCGO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DCGO at 15.2/100 on a 32-signal composite quality model, placing it at rank #2,857 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (1.4) and balance sheet strength (2.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 23.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), DocGo Inc. reports quarterly revenue of $73.4M, net income of $-15.8M, free cash flow of $-9.6M. Top institutional holders of DCGO by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, P.A.W. CAPITAL, Knott David M Jr, based on the most recent SEC filings. DCGO trades on the Nasdaq exchange and files with the SEC under CIK 1822359. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DCGO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DocGo Inc. directly from SEC EDGAR. DocGo Inc.'s 13F Pro composite quality score has ranged between 15 and 64 since 2022, currently 15.2 — a declining long-term trajectory across 64 quarterly and live scoring snapshots.

✦

Fun facts about DocGo Inc.

Quirks, history, and lore behind DCGO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare services company · small-cap · listed on Nasdaq · headquartered in New York City.
2
The Numbers
Annual revenue in the range of $500–700 million, built largely by deploying medical staff on-demand to wherever patients happen to be — not the other way around.
3
The History
Founded in the 2010s, it went public via a SPAC merger and grew rapidly by winning government and municipal contracts to bring care directly to underserved communities.
4
The Secret
Its big break came during COVID-19, when cities paid it to run mobile vaccination and testing programs — putting its fleet of clinicians on the map almost overnight.
5
The Lore
It operates a fleet of mobile health units that roll into shelters, worksites, and remote locations — think urgent care, but the clinic comes to you.
6
The Giveaway
Its name is basically a doctor making a house call, compressed into five letters — a mobile and telehealth hybrid trading under a ticker that sounds exactly like what it does.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$73.4M

Net Income

Q2 2026

$-15.8M

Free Cash Flow

Q2 2026

$-9.6M

ROIC

Q2 2026

-60.1%

D/E Ratio

Q2 2026

0.00

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-47.7% YoY

$322.2MFY 2025

FY22 $440.5MFY23 $624.3MFY24 $616.6MFY25 $322.2M

Net Income

-1012.4% YoY

$-182.4MFY 2025

FY22 $34.6MFY23 $6.9MFY24 $20.0MFY25 $-182.4M

Operating Income

-720.6% YoY

$-178.0MFY 2025

FY22 $21.8MFY23 $15.1MFY24 $28.7MFY25 $-178.0M

EPS (Diluted)

-1122.2% YoY

$-1.84FY 2025

FY22 $0.34FY23 $0.06FY24 $0.18FY25 $-1.84

Total Assets

-52.4% YoY

$217.1MFY 2025

FY22 $393.3MFY23 $490.5MFY24 $455.6MFY25 $217.1M

Total Debt

+850.0% YoY

$287.3KFY 2025

FY22 $664.9KFY23 $97.8KFY24 $30.2KFY25 $287.3K

Op. Cash Flow

-50.9% YoY

$34.5MFY 2025

FY22 $28.9MFY23 $-64.5MFY24 $70.1MFY25 $34.5M

Free Cash Flow

-55.0% YoY

$29.9MFY 2025

FY22 $-65.3MFY23 $-115.5MFY24 $66.5MFY25 $29.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$322.2M -47.7%	$616.6M -1.2%	$624.3M +41.7%	$440.5M +38.2%	$318.7M +238.7%	$94.1M
Net Income	$-182.4M -1012.4%	$20.0M +191.5%	$6.9M -80.2%	$34.6M +45.7%	$23.7M +260.4%	$-14.8M
Operating Income	$-178.0M -720.6%	$28.7M +90.6%	$15.1M -31.0%	$21.8M +42.2%	$15.4M +204.1%	$-14.8M
EPS (Diluted)	$-1.84 -1122.2%	$0.18 +200.0%	$0.06 -82.4%	$0.34 +36.0%	$0.25 +200.0%	$-0.25
Total Assets	$217.1M -52.4%	$455.6M -7.1%	$490.5M +24.7%	$393.3M +27.0%	$309.6M +166.7%	$116.1M
Total Debt	$287.3K +850.0%	$30.2K -69.1%	$97.8K -85.3%	$664.9K +10.7%	$600.4K +320.9%	$142.7K
Operating Cash Flow	$34.5M -50.9%	$70.1M +208.7%	$-64.5M -323.4%	$28.9M +1582.5%	$-1.9M +81.7%	$-10.7M
Free Cash Flow	$29.9M -55.0%	$66.5M +157.6%	$-115.5M -76.8%	$-65.3M -218.3%	$-20.5M -36.7%	$-15.0M

Get alerted when DCGO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for DocGo Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DCGO

VANGUARD CAPITAL MANAGEMENT LLC
$1.9M3,728,207 sh
P.A.W. CAPITAL CORP
$1.8M3,505,000 sh
Knott David M Jr
$1.4M2,670,850 sh
Peapod Lane Capital LLC
$1.3M2,500,118 sh
CITADEL ADVISORS LLC
$1.2M2,353,610 sh
RENAISSANCE TECHNOLOGIES LLC
$1.2M2,254,370 sh
S Squared Technology, LLC
$1.1M2,055,271 sh
ACADIAN ASSET MANAGEMENT LLC
$918.0K1,792,971 sh
AQR CAPITAL MANAGEMENT LLC
$882.0K1,708,962 sh
MOORE CAPITAL MANAGEMENT, LP
$756.1K1,465,000 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$1.9M	3,728,207
P.A.W. CAPITAL CORP	$1.8M	3,505,000
Knott David M Jr	$1.4M	2,670,850
Peapod Lane Capital LLC	$1.3M	2,500,118
CITADEL ADVISORS LLC	$1.2M	2,353,610
RENAISSANCE TECHNOLOGIES LLC	$1.2M	2,254,370
S Squared Technology, LLC	$1.1M	2,055,271
ACADIAN ASSET MANAGEMENT LLC	$918.0K	1,792,971
AQR CAPITAL MANAGEMENT LLC	$882.0K	1,708,962
MOORE CAPITAL MANAGEMENT, LP	$756.1K	1,465,000

Companies Similar to DCGO

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

MGX

Metagenomi Therapeutics, Inc.

AI score

Very similar · 5 shared holders

Peapod Lane Capital LLC Marquette Asset Management, LLC JACOBS LEVY EQUITY MANAGEMENT, INC

MXCT

MAXCYTE, INC.

AI score

Similar quality profile · 6 shared holders

Peapod Lane Capital LLC RBF Capital, LLC Marquette Asset Management, LLC

OSUR

ORASURE TECHNOLOGIES INC

AI score

Similar quality profile · 3 shared holders

Peapod Lane Capital LLC Marquette Asset Management, LLC JACOBS LEVY EQUITY MANAGEMENT, INC

GAIA

GAIA, INC

AI score

Shared smart-money ownership · 5 shared holders

Peapod Lane Capital LLC S Squared Technology, LLC RBF Capital, LLC

Outset Medical, Inc.

AI score

Similar quality profile · 3 shared holders

Peapod Lane Capital LLC Marquette Asset Management, LLC R Squared Ltd

INGN

Inogen Inc

AI score

Similar quality profile · 4 shared holders

Peapod Lane Capital LLC MOORE CAPITAL MANAGEMENT, LP Marquette Asset Management, LLC

LUNG

Pulmonx Corp

AI score

Similar quality profile · 3 shared holders

Birchview Capital, LP JACOBS LEVY EQUITY MANAGEMENT, INC R Squared Ltd

GOSS

Gossamer Bio, Inc.

AI score

Similar quality profile · 3 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Birchview Capital, LP Caerus Investment Advisors, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DCGO on your watchlist

Track score changes the day DocGo Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DCGO a good stock to buy?

13F Pro's AI-powered analysis of DocGo Inc. (DCGO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DCGO are available on the DCGO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. DCGO is classified as a small company.

Which hedge funds own DCGO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DCGO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of DocGo Inc.'s investment landscape.